Nicki Thompson

Chief Executive Officer
TRIMTECH Therapeutics

Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and commercial leadership roles. She is CEO of Cambridge-based TRIMTECH Therapeutics (an MRC LMB/UK DRI spin-out), which focuses on a novel targeted protein degradation (TPD) approach to treat neurodegenerative diseases. Nicki led TRIMTECH through its recent $31M seed financing. Nicki was also founding CEO of Amphista Therapeutics, leading the company through its series A and B financings and spearheaded Amphista’s collaborations with BMS and Merck KGaA. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s external drug discovery and external innovation groups. Nicki’s Biotech experience also includes her roles as CBO, then Chair of the Board for Nanna Therapeutics Ltd (acquired by Astellas Pharma Inc.) and Chair of the Board for Camena Bioscience. She holds a PhD in Cell Biology from University College London